Vialwirebiotech, curated
November 21, 2026, 11:07 AM
October 2, 2026
- 12:00 PM · BioWorld12:00 PMFibrous optics improving in CD as Agomab mulls phase IIb — BioWorld
- 12:00 PM · BioWorld12:00 PMNovartis taps Abogen’s RNA platform in potential $7.8B deal — BioWorld
- 12:00 PM · BioWorld12:00 PMMedicus makes melanoma ADC ‘strategic priority’ post-Pfizer deal — BioWorld
- 9:58 AM · STAT News9:58 AMSTAT+: Lilly bypasses Australian pharmacies with DTC model — STAT News
- 9:00 AM · BioWorld9:00 AMFinancing at Omnio to advance chronic wound therapy — BioWorld
- 7:30 AM · Drug Discovery World7:30 AMDr Rajesh Chopra joins Numab Therapeutics as Chief Scientific Officer — Drug Discovery World
- 4:08 AM · Drug Discovery World4:08 AMMonoclonal antibody reduces COPD exacerbations in Phase II trial — Drug Discovery World
October 1, 2026
- 12:00 PM · BioWorld12:00 PMNew CMS model saving $440M, exempts rare disease drugs — BioWorld
- 12:00 PM · BioWorld12:00 PMFoghorn cuts staff 40% as Lilly terminates SMARCA2 deal — BioWorld
- 12:00 PM · BioWorld12:00 PMAtara, Pierre Fabre take third shot at FDA approval of Ebvallo — BioWorld
- 12:00 PM · BioWorld12:00 PMRegulatory: FDA nods for Biolinq, Egetis, Elevar, Lilly, Teva and more — BioWorld
- 11:38 AM · BioPharma Dive11:38 AMSanofi, Regeneron broaden alliance to find their next Dupixent — BioPharma Dive
- 11:06 AM · BioPharma Dive11:06 AMHHS kicks off new programs to speed clinical trials as Chinese competition looms — BioPharma Dive
- 11:03 AM · BioPharma Dive11:03 AMPfizer’s eczema drug clears skin in mid-stage trial — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMDyne presents new exon skipping conjugates for DMD — BioWorld
- 9:00 AM · BioWorld9:00 AMEverzom advances Evergel toward CTA filing — BioWorld
- 9:00 AM · BioWorld9:00 AMErnexa reports IND-enabling safety results for ERNA-101 — BioWorld
- 9:00 AM · BioWorld9:00 AMGSK selects siRNA candidate from Wave Life Sciences collaboration — BioWorld
- 9:00 AM · BioWorld9:00 AMBiontech and Duality Biologics disclose new antibody-drug conjugates — BioWorld
- 9:00 AM · BioWorld9:00 AMImmunome’s ADC IM-1340 cleared for clinic in solid tumors — BioWorld
- 6:48 AM · Drug Discovery World6:48 AMMelbourne radiopharmaceuticals spinout launches with AUD$12 million — Drug Discovery World
- 6:30 AM · STAT News
- 6:24 AM · Pharmaceutical Technology6:24 AMVarda pockets $251m to back space-based pharma processing mission — Pharmaceutical Technology
- 5:21 AM · Pharmaceutical Technology5:21 AMBristol Myers Squibb secures expanded US approval for Camzyos — Pharmaceutical Technology
- 4:36 AM · Pharmaceutical Technology4:36 AMBioMarin and Profluent partner on AI-designed enzyme therapies — Pharmaceutical Technology
- 4:00 AM · Drug Discovery World4:00 AMBreye raises €67.5 million for retinal disease therapies — Drug Discovery World
September 30, 2026
- 3:58 PM · Pharmaceutical Technology3:58 PMEASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis — Pharmaceutical Technology
- 12:40 PM · Pharmaceutical Technology12:40 PMEASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis — Pharmaceutical Technology
- 12:22 PM · BioPharma Dive12:22 PMBristol Myers trial revisions shake confidence in new class of fibrosis drugs — BioPharma Dive
- 12:18 PM · Pharmaceutical Technology12:18 PMAtossa plans shareholder stake in potential PRV proceeds — Pharmaceutical Technology